Trial Search Results
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Erik Mittra
Collaborator: National Cancer Institute (NCI)
Stanford Investigator(s):
Intervention(s):
- Drug: 18F-fluoro-dihydroxyphenylalanine
- Procedure: Positron emission tomography (PET)
- Procedure: Computed tomography (CT)
- Procedure: Magnetic resonance imaging
Phase:
N/A
Eligibility
Inclusion Criteria:
- Greater than 15 year-old at the time of radiotracer administration
- Provides written informed consent
- Suspected new diagnosis or suspected recurrence of glioma
- Able to remain still for duration of each imaging procedure (about 20 minutes)
Exclusion Criteria:
- Less than 15 year-old at the time of radiotracer administra
- Unable to provide informed consent
- Inability to lie still for the entire imaging time
- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Andrei Iagaru
650-736-2859
Not Recruiting